Home WhoIs Lookup Tool
WhoIs Lookup Tool
Please use the following form to check the availability of a domain name. Please provide a value for a domain name and an extensions (i.e., “.com”, “.net”, “.org”, etc.). A query will be performed on the appropriate WHOIS database.
Today’s Health News
ASH: GLP-1 RA Use Tied to Lower Rate of Venous Thromboembolism in Diabetes
Significant reduction seen in VTE rates, with similar reductions for patients with and without obesity
AHA: More Moderate-to-Vigorous Exercise Tied to Lower Risk for A-Fib
Findings based on wearable-collected, real-world data, independent of clinical and genetic risk factors
Adverse Events Occur in More Than One-Third of Patients Admitted for Surgery
Most common adverse events related to surgical procedures, adverse drug events, health care-associated infections
Incidence of Dyslipidemia Elevated During COVID-19 Pandemic
Increased risk for developing any dyslipidemia seen during 2020 to 2022
Fasting at Night May Aid Glucose Metabolism in Night-Shift Workers
Fasting shows benefits compared with eating meals or snacks at night
E. Coli Illnesses Linked to McDonald’s Quarter Pounders Climb to 104
By Robin Foster HealthDay Reporter
THURSDAY, Nov. 14, 2024 (HealthDay News) -- The number of Americans sickened in an E. coli outbreak tied to slivered...
New U.S. Overdose Death Numbers Show ‘Sustained’ Decline
By Robin Foster HealthDay Reporter
THURSDAY, Nov. 14, 2024 (HealthDay News) -- After decades of battling the opioid epidemic, U.S. health officials reported Wednesday that...
ASH: Complications Common With Controlled Ovarian Hyperstimulation in Sickle Cell Anemia
In recent study, 25 of 55 controlled ovarian hyperstimulation cycles had complications
Continuous Psychological Distress in Pregnancy Increases Offspring Risk for Epilepsy
Findings show up to 70 percent increased risk for offspring at ages 1, 2, and 3 years
Neoantigen DNA Vaccines Safe, Induce Response in Triple-Negative Breast Cancer
Fourteen of 18 patients had neoantigen-specific T-cell responses; recurrence-free survival was 87.5 percent at 36 months